

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A method of enhancing an immune response to ~~an~~ a viral antigen comprising administering an effective amount of an agent that can augment the level of a ~~TAP~~ TAP-1 molecule or a TAP-2 molecule in a target cell bearing the viral antigen to a cell or animal in need thereof,

wherein the agent is a ~~nucleic acid sequence~~ vector comprising a nucleic acid sequence encoding ~~a TAP~~ the TAP-1 molecule or the TAP-2 molecule; and

wherein the vector is capable of transforming the target cell so that the expression of TAP-1 or TAP-2 is increased and the immune response to the viral antigen is enhanced ~~administration of the agent enhances the immune response to the antigen.~~

2. (Canceled)

3. (Original) A method according to claim 1 wherein the target cell is a virally infected cell.

4. (Canceled)

5. (Canceled)

6. (Canceled)
7. (Previously presented) A method according to claim 1 further comprising administering a nucleic acid sequence encoding an antigen.
8. (Original) A method according to claim 7 wherein the antigen is a viral antigen.
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Canceled)
14. (Original) A method according to claim 1 wherein the agent is administered intraperitoneally, subcutaneously, intravenously, orally, mucosally, submucosally or intradermally.
15. (Canceled)
16. (Cancelled)
17. (Currently amended) A method according to claim ~~16~~1 wherein the vector is a viral vector.
18. (Original) A method according to claim 17 wherein the viral vector is selected from the group consisting of vaccinia based vectors, adenovirus based vectors, lenti virus based vectors and HSV based vectors.
19. (Currently amended) A method according to claim ~~16~~1 wherein the vector is a plasmid.

20. (Previously presented) A method according to claim 19 wherein the plasmid is in a liposome formulation.

21. (New) A method of enhancing an immune response to an a tumor antigen comprising administering an effective amount of an agent that can augment the level of a TAP-1 molecule in a target cell bearing the tumor antigen to a cell or animal in need thereof,

wherein the agent is a vector comprising a nucleic acid sequence encoding the TAP-1 molecule; and

wherein the vector is capable of transforming the target cell so that the expression of TAP-1 is increased and the immune response to the tumor antigen is enhanced.

22. (New) The method according to claim 21, wherein the target cell is a tumor cell.

23. (New) The method according to claim 21, further comprising administering a nucleic acid sequence encoding an antigen.

24. (New) The method according to claim 23, wherein the antigen is a tumor antigen.

25. (New) The method according to claim 21, wherein the animal is also subjected to surgery, radiation, chemotherapy, immunotherapy or photodynamic therapy.

26. (New) The method according to claim 21, wherein the agent is administered intraperitoneally, intratumorally,